Literature DB >> 6809737

Formation of 6-oxoprostaglandin F1 alpha, 6,15-dioxoprostaglandin F1 alpha, and monohydroxyicosatetraenoic acids from arachidonic acid by fetal calf aorta and ductus arteriosus.

W S Powell.   

Abstract

Particulate fractions and slices from fetal calf aorta convert arachidonic acid to 6-oxoprostaglandin F1 alpha (6-oxoPGF1 alpha), 6,15-dioxoPGF1 alpha, 12-hydroxy-5,8,10-heptadecatrienoic acid, 11-hydroxy-5,8,12,14-icosatetraenoic acid (11h-20:4), and 15-hydroxy-5,8,11,13-icosatetraenoic acid (15h-20:4). In some cases, small amounts of 12-hydroxy-5,8,10,14-icosatetraenoic acid (12h-20:4) were also detected. The products were all identified by gas chromatography-mass spectrometry after purification by normal phase and argentation high pressure liquid chromatography. Both 11h-20:4 and 15h-20:4 appeared to be formed by prostaglandin endoperoxide synthetase rather than by lipoxygenases, since their formation was inhibited by indomethacin but not by nordihydroguaiaretic acid. The formation of 12h-20:4, on the other hand, was stimulated by indomethacin, probably due to increased substrate availability. The formation of hydroxyicosatetraenoic acids was markedly stimulated by adrenaline. Substantial amounts of 6,15-dioxoPGF1 alpha were formed from arachidonic acid by particulate fractions from fetal calf blood vessels, especially in the presence of relatively high substrate concentrations. The formation of this product was stimulated by methemoglobin and inhibited by adrenaline, glutathione, and tryptophan. It would appear that particulate fractions from fetal calf aorta convert arachidonic acid to 15-hydroperoxyPGI2, which can either be reduced in the presence of various cofactors to form PGI2 or dehydrated to give 15-oxoPGI2. The formation of hydroperoxides from arachidonic acid could be an important factor in regulating PGI2 synthesis in aorta, since PGI2 synthetase is strongly inhibited by such intermediates.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809737

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase. Potential role in diabetic vascular disease.

Authors:  B N Setty; M J Stuart
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

Review 2.  Prostaglandins, other eicosanoids and endothelial cells.

Authors:  K Schrör
Journal:  Basic Res Cardiol       Date:  1985 Sep-Oct       Impact factor: 17.165

Review 3.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.

Authors:  William S Powell; Joshua Rokach
Journal:  Biochim Biophys Acta       Date:  2014-10-29

4.  A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid.

Authors:  Evgenia Alpert; Arie Gruzman; Hanan Totary; Nurit Kaiser; Reuven Reich; Shlomo Sasson
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

5.  Fatty acid metabolism and cell proliferation. V. Evaluation of pathways for the generation of lipid peroxides.

Authors:  N Morisaki; J A Lindsey; J M Stitts; H Zhang; D G Cornwell
Journal:  Lipids       Date:  1984-06       Impact factor: 1.880

6.  Release of 15-hydroxy-5,8,11,13-eicosatetraenoic acid and cysteinyl-leukotrienes in carrageenin-induced inflammation: effect of non-steroidal anti-inflammatory drugs.

Authors:  B M Peskar; M Trautmann; P Nowak; B A Peskar
Journal:  Agents Actions       Date:  1991-07

7.  Synthesis of arachidonic acid metabolites by Syrian hamster platelets and peritoneal cells.

Authors:  M E Surette; J Whelan; G P Lu; J E Kinsella
Journal:  Lipids       Date:  1993-12       Impact factor: 1.880

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.